StockNews.com initiated coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON – Get Free Report) in a report released on Tuesday. The firm set a “hold” rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright reiterated a “neutral” rating on shares of TRACON Pharmaceuticals in a research report on Monday, July 1st.
Read Our Latest Report on TRACON Pharmaceuticals
TRACON Pharmaceuticals Stock Performance
TRACON Pharmaceuticals (NASDAQ:TCON – Get Free Report) last issued its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter. The company had revenue of $0.06 million during the quarter.
About TRACON Pharmaceuticals
TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.
Featured Articles
- Five stocks we like better than TRACON Pharmaceuticals
- How to Most Effectively Use the MarketBeat Earnings Screener
- Why Block’s Key Components Make It a Solid Investment Choice
- 5 discounted opportunities for dividend growth investors
- Is Applied Digital’s Stock Set to Surge With NVIDIA’s Backing?
- Most Volatile Stocks, What Investors Need to Know
- 4 Reasons to Consider Adding General Mills to Your Portfolio
Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.